• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec9
Amneal Pharmaceuticals Inc. Receives FDA Approval for Its Epinephrine Injection
21:01
Dec5
Amneal Pharmaceuticals' CREXONT® Shows Positive Mid-Stage Results in Parkinson's Disease Study
13:01
Dec2
Amneal Pharmaceuticals Inc. Secures FDA Approval for Respiratory Product
13:00
Dec1
Amneal Pharmaceuticals Inc. Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05% Generic Drug
21:01
Oct31
Sulewski reiterates hold rating on Amneal Pharmaceuticals
12:27
Oct30
Amneal Pharmaceuticals released FY2025 9 Months Earnings on October 30 Pre-Market (EST), actual revenue USD 2.204 B, actual EPS USD 0.1167
13:30

Schedules & Filings

Schedules
Filings
Oct30
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 784.51 M, Net Income 2.369 M, EPS 0.0075

Aug5
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 724.51 M, Net Income 22.42 M, EPS 0.07

May2
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 695.42 M, Net Income 12.2 M, EPS 0.0392

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
ASPC
24.010
+78.91%
+10.590
PCLA
0.4050
+74.49%
+0.173
DTCK
0.3951
+66.08%
+0.157
SOPA
1.820
+58.26%
+0.670
ECDA
1.150
+46.50%
+0.365
GAUZ
1.470
+44.12%
+0.450
CELG.RT
0.0698
+39.60%
+0.020
ASPCR
0.2500
+38.89%
+0.070
PAVS
2.170
+37.34%
+0.590
CUE
0.3248
+34.77%
+0.084
View More